Private Equity COVID-19 COVID-19: China Healthcare Implications for Private Equity Investors July 14, 2020 We are seeking to drive practical insight from China’s experience to inform healthcare investment
Life Sciences & Pharma COVID-19 European Disease Progression Monitor: Edition 6 May 11, 2020 The COVID-19 Disease Progression Monitor delivers evidence on the effects of the disease on services, systems and therapies
Life Sciences & Pharma COVID-19 COVID-19 and Clinical Trials: Accelerating the Adoption of eClinical Technology April 2, 2020 Interruptions to trial timelines are occurring with increasing frequency as sponsors and investigator sites feel the effects of the COVID-19 outbreak.
Life Sciences & Pharma Special Report The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments November 26, 2019 The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments: Key Findings and Implications documents the industry’s increasing commitment to…
Organization & Performance COVID-19 Agile Transformation Part 1: Unlocking the Benefits of Agile May 6, 2020 Executives and leadership teams are looking to agile as a methodology for driving organisational transformation, and as a strategy to address three…
Life Sciences & Pharma Special Report Weighing the Trade-offs of a Direct Presence in Japan’s Rare and Orphan Drug Market February 20, 2020 In recent years, there has been a marked uptick in the number of rare and orphan companies establishing local operations in Japan to steward their…
